The debate about cannabis legalization has spent a decade generating more heat than light because its central question was never quite right. Advocates argued that legalization wouldn’t increase use; opponents argued it would. Both camps treated “legalization” as a single policy variable. A study published June 17 in The Lancet Psychiatry ends that part of the argument.
The question was never whether legalization increases use. The question was which kind of legalization—and for whom.
What the study found
The global analysis, led by the University of Bath and conducted with an international research team spanning the Americas, Europe, Africa, Australia, New Zealand, and Asia, examined cannabis policy reforms across multiple regulatory models. The finding is precise and has significant implications for policy in the 38 U.S. states that have now enacted some form of cannabis reform:
Decriminalization—removing criminal penalties for personal possession while maintaining prohibitions on sale—is not associated with increased cannabis use or increased addiction rates. Tightly controlled legalization, including government-operated dispensaries with purchase limits, age restrictions, potency caps, and advertising restrictions, is similarly not associated with meaningfully increased use.
Commercial, for-profit legalization—the model adopted in the U.S. and Canada, characterized by private retail markets, relatively limited potency regulation, and aggressive marketing—is associated with increased rates of cannabis addiction, more potent products, and higher rates of hospital admissions for psychosis. In some jurisdictions, the study found increases in cases where psychotic disorders developed concurrently with cannabis addiction.
The mechanism is not complicated: a competitive for-profit market has financial incentives to maximize potency, to market aggressively, and to develop products that produce dependence and repeat purchase. A government monopoly or tightly regulated dispensary system has fewer of those incentives. The drug doesn’t change; the market structure changes what the drug becomes.
The numbers on cannabis use disorder
In the United States, approximately 19.2 million people—6.8% of the adult population—met criteria for past-year cannabis use disorder in recent NSDUH data. That figure has grown as legal commercial markets have expanded access to high-potency concentrates, vape products, and edibles.
The dependency rate is not uniform across the population. NIDA data indicates that roughly 9% of cannabis users develop dependence over their lifetime—a figure that climbs to approximately 17% among those who begin use in adolescence. High-potency products, which are now the dominant commercial form in many states, appear to accelerate this trajectory.
The Lancet Psychiatry study is notable because it provides the comparative framework that single-jurisdiction studies can’t: it allows researchers to distinguish what happens under different regulatory regimes with the same underlying substance. The substance is the same in the Netherlands (partial decriminalization), Canada (commercial legalization), and Colorado. What differs is the market.
What this means for cannabis use disorder treatment
The treatment landscape for cannabis use disorder remains limited in ways that the policy debate often obscures. There are no FDA-approved medications for cannabis use disorder—no pharmacological equivalent of buprenorphine for opioids or naltrexone for alcohol. The evidence-based treatment options are behavioral: cognitive behavioral therapy, motivational enhancement therapy, and contingency management. These work, but they require clinical infrastructure and consistent engagement.
Duke University researchers have been exploring neuromodulation—specifically repetitive transcranial magnetic stimulation—as a potential cannabis use disorder treatment, with early data suggesting some promise in reducing craving. Digital platforms have shown utility as adjuncts to behavioral therapy, providing real-time monitoring and intervention between clinical appointments. Neither approach is yet ready to replace the fundamental limitation: most people with cannabis use disorder never seek or receive treatment.
The treatment gap for cannabis use disorder mirrors the broader SUD treatment gap: approximately 15% of Americans with any substance use disorder receive treatment. For cannabis specifically, the stigma dynamics are different—cannabis use disorder is often dismissed as “not a real addiction”—but the outcome is the same. People don’t get help.
For cannabis specifically, the stigma dynamics are different—cannabis use disorder is often dismissed as “not a real addiction”—but the outcome is the same.
The policy implication the industry will resist
The Lancet Psychiatry finding is important for state legislatures currently weighing cannabis policy, and for the federal legalization debate that has been building for years. It is not an argument against legalization—the study explicitly finds that decriminalization and tightly controlled legalization do not increase use. It is an argument about what kind of legalization produces harm.
The U.S. commercial cannabis industry has significant political power and has successfully opposed potency caps, advertising restrictions, and other regulatory tools in most markets where it operates. The Lancet Psychiatry data suggests those tools matter—that the difference between a government monopoly model and a Walgreens-of-weed model is measurable in addiction and psychosis rates.
The research community has known for years that potency is the key variable: high-THC products (above 20%) are disproportionately associated with adverse mental health outcomes, particularly psychosis, compared to lower-potency flower. The Lancet Psychiatry study adds the market structure layer: it’s not just what’s in the product, it’s the incentive structure that determines what gets produced and how aggressively it’s promoted.
For the 48.5 million Americans with a substance use disorder—and for the policy apparatus trying to address that crisis—the cannabis data adds a specific kind of complexity. Commercial cannabis legalization, in its current U.S. form, appears to be adding to the population that needs treatment, not reducing it. That’s not an argument for returning to criminalization, which the study confirms doesn’t help either. It’s an argument for taking the “tightly controlled” part of “tightly controlled legalization” seriously—before the market embeds itself further and makes regulation politically harder.
The study was published. Now comes the harder part.
The Rize Newsroom tracks cannabis policy and science as part of its substance coverage mission. Browse the full research roundup archive for peer-reviewed findings from this week.
Sources Cited
- 01.ALegalizing cannabis increases use and addiction – unless it is tightly controlledEurekAlert / University of Bath
- 02.A
Filed Under
sciencepolicysocial-culturalCannabisHarm ReductionPolicy
Keep up with the reporting.
One email each morning with the stories that put days like this in context.